{"id":"W3094745505","doi":"10.1158/1078-0432.ccr-20-1830","title":"OX40 Agonist BMS-986178 Alone or in Combination With Nivolumab and/or Ipilimumab in Patients With Advanced Solid Tumors","year":2020,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":110,"is_retracted":false,"has_abstract":true,"ca_institutions":"Alberta Cancer Foundation; Ottawa Hospital; Ottawa Regional Cancer Foundation; Princess Margaret Cancer Centre","funders":"Ono Pharmaceutical; Fundació Institut de Recerca Hospital Universitari Vall d’Hebron; Bristol-Myers Squibb","keywords":"Nivolumab; Ipilimumab; Medicine; Combination therapy; Internal medicine; Rash; Adverse effect; Pharmacodynamics; Oncology; Clinical endpoint; Pharmacology; Cancer; Pharmacokinetics; Clinical trial; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00109986,0.0001821863,0.0006249964,0.0001731183,0.00009377999,0.00003929869,0.0001739684,0.0001266089,0.0002773978],"category_scores_gemma":[0.000506395,0.0001129889,0.00004427166,0.001249797,0.0006482148,0.0001457342,0.00008678449,0.0009449655,0.000008631142],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003607818,"about_ca_system_score_gemma":0.001125398,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008170835,"about_ca_topic_score_gemma":0.004059207,"domain_scores_codex":[0.9970307,0.0002956968,0.0006947367,0.0006216154,0.0008338962,0.0005233758],"domain_scores_gemma":[0.9985406,0.0004812164,0.0001152461,0.0002859303,0.0002980486,0.0002789185],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.305537,0.001333161,0.5934204,0.0002998852,0.0000912593,0.0002247134,0.0006511422,0.00000960158,0.0001476626,0.000008522201,0.001022803,0.09725379],"study_design_scores_gemma":[0.06454004,0.0210554,0.9081944,0.001083795,0.00001970808,0.000004528206,0.0006536375,0.0002691937,0.0003467184,0.00001358239,0.003577817,0.0002412121],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9894376,0.000402848,0.000006825195,0.00839047,0.00005822818,0.001443962,0.00001614765,0.00002840904,0.0002154481],"genre_scores_gemma":[0.9968228,0.0009292173,0.0002000744,0.001295859,0.00009094301,0.0002011453,0.00003154569,0.00004190348,0.0003865633],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3147739,"threshold_uncertainty_score":0.4607552,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1147904643759577,"score_gpt":0.4554999773211006,"score_spread":0.3407095129451428,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}